Bcl-2 is known to be more highly expressed in non-GCB DLBCL and we know that this subtype is associated with poorer clinical outcomes when compared to GCB DLBCL [4,5]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.